Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Gabapentin Enacarbil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabapentin Enacarbil SCHEMBL977603 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL12152103 | 0.89 | SLC18A2 (0.30) | SLC18A2 | |
| SCHEMBL24850 | 0.89 | ALDH1A1 (0.41) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL25397 | 0.88 | ALDH1A1 (0.40) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL828002 | 0.88 | ALDH1A1 (0.40) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL828104 | 0.88 | ALDH1A1 (0.40) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL24785 | 0.88 | ALDH1A1 (0.40) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| Gabapentin Enacarbil SCHEMBL1077726 | 0.87 | — | — | |
| SCHEMBL15984575 | 0.86 | CTSK (0.33) | LMNA | |
| SCHEMBL1746363 | 0.86 | ALDH1A1 (0.45) | ALDH1A1CYP1A2TSHRUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-12578348-B2 | Blood indicators of Alzheimer's disease | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2026-03-17 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-20250382671-A1 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN CIRCULATING BODILY FLUIDS | Brain Chemistry Labs (US) | 2025-12-18 | — | — | US | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | claimed |
| EP-3881845-B1 | COMBINATION OF TRAZODONE AND GABAPENTIN FOR THE TREATMENT OF PAIN | ACRAF (IT) | 2025-01-15 | — | — | EP | claimed |
| WO-2024224329-A1 | COMPOSITIONS COMPRISING A CANNABINOID AND A NON-CANNABINOID, NON-TERPENE COMPOUND | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| WO-2024189127-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | PROLEVI BIO AB (SE) | 2024-09-19 | — | — | WO | claimed |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | XENOPORT, INC. | 2007-03-01 | — | — | US | claimed |
| EP-1677767-A2 | CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG | Xenoport, Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| EP-1677812-A2 | TREATING OR PREVENTING RESTLESS LEGS SYNDROME USING PRODRUGS OF GABA ANALOGS | Xenoport, Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| US-20060141034-A1 | GABA analog prodrug sustained release oral dosage forms | XENOPORT, INC. | 2006-06-29 | — | — | US | claimed |
| WO-2006050514-A1 | GABAPENTIN PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS | XENOPORT, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| WO-2005089872-A2 | TREATMENT OF LOCAL PAIN | XENOPORT, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050192353-A1 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2005-09-01 | — | — | US | claimed |
| US-20050154057-A1 | Crystalline 1-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid; may be used as therapeutic agents in the treatment of neuropathic pain and post-herpetic neuralgia | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2005-07-14 | — | — | US | claimed |
| WO-2005037784-A2 | CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG | XENOPORT, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2005027850-A2 | TREATING OR PREVENTING RESTLESS LEGS SYNDROME USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2005-03-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060141034-A1 | GABA analog prodrug sustained release oral dosage forms | GABRB1, GABRB2, GABRA1 | CACNA2D1 285/4885ALDH1A1 144/4885CYP1A2 486/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | CACNA2D1 4367/4885ALDH1A1 4056/4885CYP1A2 1906/4885 |
| US-20050154057-A1 | Crystalline 1-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid; may be used as therapeutic agents in the treatment of neuropathic pain and post-herpetic neuralgia | GABRB1, GABRP, GABRA1 | CACNA2D1 282/4885ALDH1A1 798/4885CYP1A2 4021/4885 |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | GABBR1, GABRE, GABRB2 | CACNA2D1 948/4885ALDH1A1 764/4885CYP1A2 243/4885 |
| US-12578348-B2 | Blood indicators of Alzheimer's disease | COMT, MAOB, ACHE | CACNA2D1 148/4885ALDH1A1 317/4885CYP1A2 629/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | CACNA2D1 2639/4885ALDH1A1 4516/4885CYP1A2 1214/4885 |
| US-20050192353-A1 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs | GABRB1, GABBR2, GABARAPL1 | CACNA2D1 703/4885ALDH1A1 1006/4885CYP1A2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.